Epinephrine Market Forecasts to 2030 – Global Analysis By Product (Auto-injector, Prefilled Syringe and Ampoules & Vials), Distribution Channel (Online Pharmacies, Hospital Pharmacies and Retail Pharmacies), Application and By Geography

Epinephrine Market Forecasts to 2030 – Global Analysis By Product (Auto-injector, Prefilled Syringe and Ampoules & Vials), Distribution Channel (Online Pharmacies, Hospital Pharmacies and Retail Pharmacies), Application and By Geography

According to Stratistics MRC, the Global Epinephrine Market is accounted for $2.05 billion in 2023 and is expected to reach $4.87 billion by 2030 growing at a CAGR of 13.1% during the forecast period. Epinephrine is one of the most often used medications and hormones for treatment in various situations, including emergency treatment of type 1 hypersensitivity reactions such as anaphylaxis and allergic reactions brought on by foods, medicines, latex, insect bites, or stings. It functions by relaxing the airway muscles and constricting the blood vessels. The injection is offered in a variety of forms, including vials for subcutaneous injection, prefilled automated injection devices that already have the solution inside, and others. At the first indication of a severe allergic response, the injection is often administered as needed. Epinephrine acts swiftly to enhance breathing, speed up the heart, boost blood pressure, stop hives, and lessen facial, lip, and neck swelling.

According to the American College of Allergy, Asthma & Immunology (ACAAI), allergies are among the 6th leading causes of chronic diseases in the U.S. and have health expenditures of more than USD 18.00 billion. Also, more than 50 million Americans suffer from allergies every year.

Market Dynamics

Driver

Growing prevalence of anaphylaxis

Anaphylaxis is an acute allergic reaction to an antigen. It might occur seconds or minutes after the patient is exposed to an allergen. The first choice drug for anaphylaxis therapy is epinephrine. It avoids or lessens upper airway mucosal edema, hypotension, and shock by vasoconstrictor actions. Both developing and affluent nations are seeing an increase in demand for these items as anaphylaxis rates raise internationally. Major epinephrine market companies are concentrating on creating technologically sophisticated injectors in order to meet this expanding demand. Additionally, the approval of the generic version of these injectors by governments from different nations has substantially accelerated the market growth.

Restraint

Inadequate reimbursement policies

People are generally unaware of the anaphylactic treatment choices in poor nations. Since it should always be handled as a medical emergency, the government provides particular requirements to help reduce the high cost of medical assistance. However, the laws governing auto-injector reimbursement are insufficient. Another reason for the poor uptake of auto-injectors in developing nations is a lack of R&D activity. However, the availability of substitute medication delivery methods and the inadequate reimbursement environment are limiting the market expansion.

Opportunity

Adoption of AI

Modern therapy choices have increased due to the increasing frequency of medical illnesses involving anaphylaxis, cardiovascular diseases, respiratory diseases (asthma), and others. AI replicates clinical trials and offers insights into prospective outcomes by producing synthetic patient data. Informed judgments on which medications to commercialize and how to create clinical trials that are more successful and efficient can thus be made by pharmaceutical firms. AI-enabled injectors make self-administration simple, boost patient compliance, lessen anxiety, and provide precise dosage. Growing innovations in auto-injectors, such as those with AI capabilities and needle-free auto-injectors are opening up the lucrative potential for the marketplace.

Threat

High cost of auto-injectors

Auto-injectors are used to treat severe allergic responses (anaphylaxis) and asthma attacks during medical emergencies. The demand for these injections is rising quickly because to the growing need for efficient treatment alternatives for severe allergic responses, such as anaphylaxis. Thus, the high price of these types of injectors, coupled with patients' growing need for effective treatment choices and the higher out-of-pocket costs related to the auto-injectors, are partially responsible for the less worthy market penetration of these products.

Covid-19 Impact

The corona epidemic had a detrimental effect on the expansion of the epinephrine market worldwide. The identification and treatment of various disorders, including anaphylaxis, declined as a result of the decrease in patient visits to healthcare facilities. More than 40% of major firms saw sales declines. Additionally, during the COVID-19 epidemic, the market's development was constrained by disruptions in the supply chain and the manufacturers of these auto-injectors. However, the measures implemented by governments of many nations for the control of allergic responses during the COVID-19 pandemic helped the market's expansion in the post-pandemic period.

The auto-injectors segment is expected to be the largest during the forecast period

The auto-injectors segment is estimated to have a lucrative growth, due to its wide range of benefits. It is the most prevalent variety of disposable, single-use, spring-loaded syringe. Auto-injectors can be used to treat acute anaphylaxis in cases of urgency and delivered intramuscularly. It manages asthma episodes and severe allergic responses (anaphylaxis). This medicine is injected either into a muscle or subcutaneously. It functions by contracting the blood vessels and relaxing the muscles of the airways. They are also simple to use, easy to find, and easy to transport, thereby creating demand for these products in the market.

The cardiac arrest segment is expected to have the highest CAGR during the forecast period

The cardiac arrest segment is anticipated to witness the fastest CAGR growth during the forecast period. Cardiac arrest is characterized by an abrupt loss of respiration, cardiac function, and consciousness. The heart's ability to pump blood across the body, including the brain and lungs, is typically disrupted. The main medication used in CPR to reverse the symptoms of cardiac arrest is epinephrine. Epinephrine is continuously infused into the patient during cardiac arrest to lower the danger of blood flow. During CPR, the adrenergic effects of epinephrine boost cerebral and myocardial blood flow. Its abilities to stimulate -adrenergic receptors are fuelling the segment demand.

Region with largest share

Asia Pacific is projected to hold the largest market share during the forecast period. This region has a significant prevalence owing to modifying regulatory policies for the adoption of auto-injectors. To fulfil the demand, Asian businesses are growing their worldwide footprint. In China, Taiwan, and South Korea, epinephrine enterprises are expanding technological and medicinal advances. Health systems across the region are leveraging generic medications increasingly to minimize costs. The market demand is also being fuelled by factors like superior R&D programs and efforts, first-rate healthcare infrastructure, and superior reimbursement practices in the area.

Region with highest CAGR

Europe is projected to have the highest CAGR over the forecast period, owing to the growth of technologically advanced products. There is raising prevalence of various disorders such as anaphylaxis, cardiovascular diseases, and others in this region. Europe has a high prevalence of wheat allergies. 61.6% of people in the region, according to various European publications, have food allergies. The region's elderly population and a stronger government commitment to providing affordable healthcare are driving forces behind the need for epinephrine.

Key players in the market

Some of the key players profiled in the Epinephrine Market include Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Novartis AG, Amneal Pharmaceuticals, Viatris Inc, Lincoln Medical Centre Ltd., Kaleo Inc, Aurum Pharma Lab, Bausch Health Companies, Medeca Pharma AB, Antares Pharma, Inc., Mylan N.V., Impax Laboratories LLC, Adamis Pharmaceuticals Corporation, Amedra Pharmaceuticals, ALK Abello A/S, Sanofi S.A., Grand Pharma, Harvest Pharmaceuticals and Bioprojet Pharma.

Key Developments

In November 2021, Mylan N.V. and Upjohn, Pfizer Inc.’s division formed a global pharmaceutical company called Viatris Inc. to develop products in therapeutic areas such as central nervous system and anaesthesia, infectious disease, and cardiovascular diseases around the world.

In October 2021, Bausch Health Companies Inc. launched Emerade injection of dosages 0.3mg and 0.5mg in Canada for the emergency treatment of anaphylactic reactions in patients. This product launch created a new treatment option for anaphylaxis in Canada.

In May 2021, Kaleo, Inc. announced the availability of ALLERJECT auto-injector injection in Canada. With this availability, Canadian patients could access different treatment options for anaphylaxis.

In August 2019, Teva Pharmaceutical Industries announced the availability of the FDA-approved generic version of EpiPen Jr®1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S. The product is available in most retail pharmacies, and the Wholesale Acquisition Cost is $3002 for a 2-pack.

In July 2019, Novartis announced the US retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and paediatric doses immediately available in local pharmacies across the nation.

Products Covered
• Auto-injector
• Prefilled Syringe
• Ampoules & Vials

Distribution Channels Covered
• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Applications Covered
• Superficial Bleeding
• Anaphylaxis
• Respiratory Disorders
• Cardiac Arrest
• Other Applications

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements